pioglitazone has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Breidert, T; Callebert, J; Heneka, MT; Hirsch, EC; Landreth, G; Launay, JM | 1 |
| Emborg, M; Swanson, C | 1 |
2 other study(ies) available for pioglitazone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; Animals; Cell Count; Cell Survival; Corpus Striatum; Disease Models, Animal; Dopamine; Homovanillic Acid; Hypoglycemic Agents; Immunohistochemistry; Macrophage-1 Antigen; Male; Mice; Mice, Inbred C57BL; Neuroglia; Neurons; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Parkinsonian Disorders; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Substantia Nigra; Thiazoles; Thiazolidinediones; Transcription Factors; Tyrosine 3-Monooxygenase | 2002 |
Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Count; Central Nervous System Agents; Dopaminergic Neurons; Fluorescent Antibody Technique; Immunohistochemistry; Macaca mulatta; Male; Neurons; Parkinsonian Disorders; Photomicrography; Pioglitazone; PPAR gamma; Putamen; Substantia Nigra; Thiazolidinediones; Time Factors; Tyrosine 3-Monooxygenase | 2014 |